Propanc Biopharma plans to investigate ‘mesenchymal drift’

Propanc Biopharma (PPCB) announced plans to investigate the phenomenon of “mesenchymal drift”-an emerging area of research that may help unlock the mechanisms behind the reversal of chronic diseases. The concept, advanced by leaders in the field including Altos Labs, aligns with Propanc’s expanding research efforts into how its lead product candidate, PRP, may influence the epithelial-to-mesenchymal transition, EMT, and related pathways central not only to cancer progression but also other chronic diseases. “Our cells naturally become more mesenchymal over time, so PRP’s ability to potentially reverse this trend is of tremendous scientific interest,” said Dr. Julian Kenyon, Propanc’s Chief Scientific Officer. Professor Macarena Peran, Joint Lead Researcher from the University of Jaen in Granada, Spain, concurred, adding, “PRP is a strong candidate for chronic diseases such as cancer and fibrosis.”